travellinglight/iStock through Getty Images
Shortly after a U.Ok. watchdog declined to endorse Biogen’s (NASDAQ:BIIB) Alzheimer’s drug Leqembi to be used within the nation’s nationwide well being service (NHS), The Telegraph reported Saturday that their Eli Lilly (NYSE:LLY) will face the identical destiny for its drug, donanemab.
The National Institute for Health and Care Excellence (NICE), which units drug coverage for the NHS, issued draft steerage on Friday, noting that the usage of Leqembi within the NHS wouldn’t be a cheap approach of spending taxpayer cash.
Its rebuke got here shortly after the U.Ok. drug regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), authorised the anti-amyloid infusion, making Great Britain the primary European nation to approve the remedy.
However, citing well being sources, the newspaper stated that the NHS would “undoubtedly” reject LLY’s drug, donanemab.
Based on the drug’s aspect impact profile, the paper added that the MHRA could not even approve donanemab, which requires a month-to-month administration as opposed to Leqembi’s biweekly routine.
“Now that Nice has rejected lecanemab, it undoubtedly won’t approve donanemab, which additionally has twice the danger of significant unwanted effects,” a supply stated.
Branded within the U.S. as Kisunla, donanemab has the same mechanism however is probably going to be much more costly with an annual price ticket of £25K, 25% increased than Leqembi’s.
Eli Lilly (LLY) and Biogen’s associate for Leqembi Eisai (OTCPK:ESALF) (OTCPK:ESAIY) have but to reply to feedback. MHRA and NICE declined to touch upon ongoing opinions.
More on Biogen, Eisai, and so forth.
Source: Seekingalpha